Insider Trading & Ownership of Christopher Cabell

Location
San Diego, CA
Summary
The estimated net worth of Christopher Cabell is at least $2,001,368 dollars as of 24 Feb 2026. Christopher Cabell is the President & Head of R&D of Inhibikase Therapeutics, Inc. and owns shares of Inhibikase Therapeutics, Inc. (IKT) stock worth about $1.35M. Christopher Cabell is the CMO & Head of R&D of Zura Bio Ltd and owns shares of Zura Bio Ltd (ZURA) stock worth about $648.2K.
Signature
/s/ Mark Iwicki, attorney-in-fact
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Christopher Cabell and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.

Sign up to save research and follow filings

Quick Takeaways

  • Christopher Cabell has 3 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $2,001,368.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Inhibikase Therapeutics, Inc. ($1,353,128).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Christopher Cabell

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
IKT Inhibikase Therapeutics, Inc. President & Head of R&D $1,353,128 21 Feb 2026
ZURA Zura Bio Ltd CMO & Head of R&D $648,240 18 May 2023
PULM Pulmatrix, Inc. Director 26 Jan 2023

Insider Transactions Reported by Christopher Cabell:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .